

## Putting NICE guidance into practice

### **Costing statement: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)**

Published: September 2015

Edoxaban provides another option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors including congestive heart failure, hypertension, diabetes, prior stroke or transient ischaemic attack, or age 75 years or older. Because it is an alternative to rivaroxaban, dabigatran etexilate and apixaban and the 4 drugs are similarly priced, NICE does not anticipate a significant impact on resources as a result of implementing the guidance.

This technology is commissioned by clinical commissioning groups (CCGs). Providers are secondary care providers (hospitals) and primary care providers (GPs).

This costing statement accompanies the NICE technology appraisal guidance on [edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation](#) and should be read in conjunction with it. See [terms and conditions](#) on the NICE website.

© National Institute for Health and Care Excellence, 2015. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.